Jay Yoon
Founder & Portfolio Manager of Summit Ridge Capital Management
Personalis is rising because shareholders look increasingly likely to reject Tempus's takeover, not on hopes of a competing bid, so Craig-Hallum's downgrade misreads the move. Its Next platform will likely generate over $500 million of annual revenue, whatever Craig-Hallum says about the MRD market dwarfing Personalis's potential Moderna revenue. x.com
Personalis is the more attractive risk-adjusted play because Tempus AI will likely raise its takeover bid meaningfully to close the deal. Personalis trades near $17, above the $16.25 deal price, as the market prices in a bump. The valuation gap is so extreme that it will likely draw opposition, possibly an activist campaign or behind-the-scenes pressure from large holders, and even with Tempus and Merck owning 25.5% of shares, approval is far from guaranteed. x.com x.com x.com
Tempus AI's $1.5B all-stock acquisition of Personalis is smart long-term positioning despite the dilution-driven dip. Owning Personalis's NeXT Personal MRD technology outright lets Tempus pair liquid-biopsy recurrence testing, one of oncology's fastest-growing areas, with its multimodal dataset and AI at scale. That extends Tempus from diagnostics into high-margin longitudinal monitoring and could strengthen its moat, though execution will decide it. x.com
Tempus AI's $1.5 billion all-stock acquisition of Personalis strengthens its position in precision oncology, adding Personalis' MRD platform, expanding its AI-driven diagnostics business and widening its opportunity in a market estimated at about $20 billion. The 6% drop on the news reflects dilution, timing ahead of earnings and near-term integration risk, a classic case of short-term dilution overshadowing long-term strategy. x.com x.com
Personalis no longer offers the hoped-for path to a Tempus stock swap, because its premium to the Tempus deal price makes a knockout cash offer the likelier outcome if the deal breaks. Tempus, Merck and other deal supporters own much of the equity, so a rival bid would need to be undeniably better and would probably be cash, nullifying the reason to hold even at a higher price. Biodesix looks more discounted, with 82% gross margins, 35% growth and a valuation below 3x revenue. x.com
Tempus AI's deal for Personalis has some protection, though it is not guaranteed. There is a $78.6 million termination fee, and Merck, which owns 14 million Personalis shares, voted for the merger on July 20. The risk is higher now that Personalis trades above the buyout price, especially if another bidder appears. x.com
Tempus AI's Personalis acquisition is a great strategic fit but raises the risk profile, because Tempus overpaid. Personalis adds longitudinal molecular-response and patient-outcome data that reinforce Tempus's data moat. But at roughly 19 times Personalis's guided 2026 revenue, with 15-20% gross margins and about $100M of cash burn, it adds burn on top of Tempus's own and could take years to become accretive. The thesis needs many years of patience and near-flawless execution. x.com x.com
Tempus AI's growth story has become a real one, with Q2 revenue up 22% to $382.5 million, positive net income and EBITDA, a 73.5% gross margin and $816 million of cash. Its $1.5 billion Personalis deal owns the sequencing technology behind the Moderna-Merck mRNA cancer vaccine, whose strong Phase 3 melanoma results validated the bet. Piper Sandler upgraded it to Overweight with a $76 target, up from $56, citing Personalis and strong INTerpath-001 MRD data. $80 is support for the breakout. x.com
Tempus AI is becoming a bigger health-tech player as pharma deals add a new services revenue stream beyond selling tests. BTIG's Mark Massaro raised his target to $80 from $70 with a Buy rating, mainly because Tempus will be the sequencing provider for Moderna and Merck's cancer vaccine program. The Personalis deal and MRD momentum add to a strengthening long-term AI and precision-oncology story, despite near-term volatility. x.com
Voyager's single-molecule approach could make Nautilus the most asymmetric proteomics bet if it works. Quarterly grant revenue of about $0.2m against over $10m consumed leaves it reliant on capital; a $125m ATM risks dilution. Repeated slips make the mid-2027 launch less likely to hold; independent customer validation and a sales channel are absent. Adoption could justify billions; delay or low-price issuance could send shares below $2 again. Tempus AI remains the preferred larger holding. x.com
Tempus AI's acquisition of Personalis gives it the technology platform behind Moderna's and Merck's recent cancer-vaccine advances. x.com
Tempus AI's Moderna and Merck collaboration puts its oncology data and algorithms to work on cancer vaccines and immuno-oncology drugs, supporting the commercial value of its pharma data platform. The multiyear agreement adds to its licensing case; Q2 revenue rose more than 21.6% to $382 million, and the EPS loss of $0.04 beat the expected $0.20 loss. Sustained profitability remains prospective. Tempus AI could reach $145. x.com
